Trials / Terminated
TerminatedNCT00367692
Study Evaluating PSI-697 in Patients With Scleritis
An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PSI-697 |
Timeline
- Start date
- 2006-09-01
- Completion
- 2007-04-01
- First posted
- 2006-08-23
- Last updated
- 2009-09-09
Source: ClinicalTrials.gov record NCT00367692. Inclusion in this directory is not an endorsement.